What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Immunology, Immunotherapy, Antigen, Chimeric antigen receptor and Cancer research are his primary areas of study.
His Immunology research is multidisciplinary, relying on both Cytotoxic T cell and Internal medicine.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Surgery.
The Immunotherapy study which covers Chronic lymphocytic leukemia that intersects with Targeted therapy.
The concepts of his Antigen study are interwoven with issues in Adoptive cell transfer and T-cell receptor.
His work is dedicated to discovering how Chimeric antigen receptor, Receptor are connected with Mutation and other disciplines.
His most cited work include:
- Chimeric antigen receptor T cells for sustained remissions in leukemia. (2837 citations)
- Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. (2270 citations)
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (1779 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Immunology, Chimeric antigen receptor, Cancer research and Oncology.
His Internal medicine research includes elements of Gastroenterology and Surgery.
His study in Chimeric antigen receptor is interdisciplinary in nature, drawing from both Antigen, CD19 and Cell therapy.
His studies deal with areas such as Sirolimus, Lymphoblastic Leukemia, Apoptosis, PI3K/AKT/mTOR pathway and Receptor as well as Cancer research.
Stephan A. Grupp has included themes like Clinical trial, Young adult, Minimal residual disease, Stem cell and Neuroblastoma in his Oncology study.
Stephan A. Grupp combines subjects such as Tocilizumab, Chimeric Antigen Receptor T-Cell Therapy and Refractory with his study of Cytokine release syndrome.
He most often published in these fields:
- Internal medicine (60.13%)
- Immunology (48.95%)
- Chimeric antigen receptor (36.08%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (60.13%)
- Chimeric antigen receptor (36.08%)
- Oncology (31.22%)
In recent papers he was focusing on the following fields of study:
Stephan A. Grupp mostly deals with Internal medicine, Chimeric antigen receptor, Oncology, Cancer research and CD19.
His study brings together the fields of Gastroenterology and Internal medicine.
His Chimeric antigen receptor research incorporates themes from Leukemia and Cell therapy.
His Oncology research includes themes of Hematopoietic stem cell transplantation, Disease, Clinical trial, B cell and Acute lymphocytic leukemia.
His Immunotherapy research incorporates themes from Neoplasm genetics and Antigen.
His T cell study results in a more complete grasp of Immunology.
Between 2018 and 2021, his most popular works were:
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells (508 citations)
- Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. (78 citations)
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (65 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Stephan A. Grupp focuses on Chimeric antigen receptor, Internal medicine, Antigen, Immunotherapy and Cell therapy.
The various areas that Stephan A. Grupp examines in his Chimeric antigen receptor study include Cancer research and Disease.
The study of Internal medicine is intertwined with the study of Oncology in a number of ways.
Adoptive cell transfer, Tumor microenvironment and Cytokine is closely connected to Progressive disease in his research, which is encompassed under the umbrella topic of Antigen.
His research on Immunotherapy often connects related topics like T cell.
His research integrates issues of Gastroenterology, Tocilizumab and Refractory in his study of Cytokine release syndrome.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
